$EXASGreen: Entry Point
Blue: Start of Week
Red: End of Week
Thumbs Up: Trade Available for Week
Numbers: Price Targets
*For share traders only. Not meant for options.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.17 USD
−204.15 M USD
2.50 B USD
182.38 M
About Exact Sciences Corporation
Sector
Industry
CEO
Kevin T. Conroy
Website
Headquarters
Madison
Founded
1995
FIGI
BBG000CWL0F5
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
EXAS a Bullish OutlookAs I predicted before, I had a 100% success rate. Let's consider a long position based on the current technical indicators.
Trend Line: We have a yellow trend line where the price bounced in 2016 and 2022. We are now approaching this trend line again.
Bat Pattern: The bat pattern indicates that poi
Exact Sciences: Anticipating a Market Correction Amidst OverbougExact Sciences is exhibiting bullish tendencies at present, but it's critical to anticipate a substantial correction upon touching, or descending below, the 0.618 Fibonacci retracement level. The stock is likely to retreat to around $70, a significant support level we've observed. The patterns in pl
Exact Sciences (EXAS) - Continuation of the DowntrendBased on my previous technical analysis where Exact Sciences exhibited bullish tendencies but warned of a possible substantial correction around the $70 level, we now find ourselves at a critical junction. Two possible scenarios could unfold from here: a bearish three drives pattern leading to a bou
ABC Correction looks to be over for EXASCorrection could now be over @ 62% retrace.
Looking for a move up to the upper trend line into 2027 based on previous cycles.
+ Momentum divergence at the c wave low suggests energy is building for the next move higher.
Trendchanges and its author are not registered financial advisors. Every
Exact Sciences Corporation Fundamentally The Company have a really good quarterly results and is looking cheap at this price. Technically we can see buying pressure from good area of support. Price might go as high as 84.50/85.50 $ before next quarterly results.
EXAS - Amazing symmetry
If you want to know where price is going to be, look for the history. Will this break out of this range and head higher or flush below?
if it can close above 65 this week, I would keep an eye on it above 68. It moves quickly so a news could push this over/under.
Long via commons and optio
Exact sciences corp Exact Sciences is a biotech stock that is overpriced.
It's time to sell
We touched 3 times the resistance line of a rising wedge pattern, impulsive wave pattern, and RSI 71 weekly overbought zone, the Q2 doesn't seem good.
A leg down to 60$ retesting 69$ which is the resistance line of a rising
Long Trade in EXASExact Sciences is a biotech stock showing high relative strength.
Following a 50% jump in January, the stock is tightening with pullbacks getting shallower from left to right.
This is a sign of seller digestion which we often see before a new breakout to the upside.
EXAS is also finding support a
$EXAS Setting UpI am not looking to take any more risk tomorrow but $EXAS is setting up an early turn low risk entry.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
EXAS4957195
Exact Sciences Corporation 0.375% 01-MAR-2028Yield to maturity
4.93%
Maturity date
Mar 1, 2028
EXAS4806408
Exact Sciences Corporation 0.375% 15-MAR-2027Yield to maturity
4.47%
Maturity date
Mar 15, 2027
EXAS5793007
Exact Sciences Corporation 1.75% 15-APR-2031Yield to maturity
3.72%
Maturity date
Apr 15, 2031
EXAS5549793
Exact Sciences Corporation 2.0% 01-MAR-2030Yield to maturity
2.66%
Maturity date
Mar 1, 2030
EXAS4586328
Exact Sciences Corporation 1.0% 15-JAN-2025Yield to maturity
1.77%
Maturity date
Jan 15, 2025
Explore more bonds
Curated watchlists where EXAS is featured.
Frequently Asked Questions
The current price of EXAS is 52.70 USD — it has decreased by −2.26% in the past 24 hours. Watch Exact Sciences Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Exact Sciences Corporation stocks are traded under the ticker EXAS.
EXAS stock has risen by 4.90% compared to the previous week, the month change is a −25.83% fall, over the last year Exact Sciences Corporation has showed a −21.50% decrease.
We've gathered analysts' opinions on Exact Sciences Corporation future price: according to them, EXAS price has a max estimate of 85.00 USD and a min estimate of 60.00 USD. Watch EXAS chart and read a more detailed Exact Sciences Corporation stock forecast: see what analysts think of Exact Sciences Corporation and suggest that you do with its stocks.
EXAS reached its all-time high on Jan 25, 2021 with the price of 159.54 USD, and its all-time low was 0.22 USD and was reached on Nov 21, 2008. View more price dynamics on EXAS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EXAS stock is 5.18% volatile and has beta coefficient of −0.38. Track Exact Sciences Corporation stock price on the chart and check out the list of the most volatile stocks — is Exact Sciences Corporation there?
Today Exact Sciences Corporation has the market capitalization of 9.98 B, it has decreased by −8.33% over the last week.
Yes, you can track Exact Sciences Corporation financials in yearly and quarterly reports right on TradingView.
Exact Sciences Corporation is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
EXAS earnings for the last quarter are −0.21 USD per share, whereas the estimation was −0.20 USD resulting in a −7.20% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Exact Sciences Corporation earnings.
Exact Sciences Corporation revenue for the last quarter amounts to 708.65 M USD, despite the estimated figure of 716.80 M USD. In the next quarter, revenue is expected to reach 694.91 M USD.
EXAS net income for the last quarter is −38.24 M USD, while the quarter before that showed −15.81 M USD of net income which accounts for −141.88% change. Track more Exact Sciences Corporation financial stats to get the full picture.
No, EXAS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 6.60 K employees. See our rating of the largest employees — is Exact Sciences Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exact Sciences Corporation EBITDA is −21.95 M USD, and current EBITDA margin is −3.05%. See more stats in Exact Sciences Corporation financial statements.
Like other stocks, EXAS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exact Sciences Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Exact Sciences Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Exact Sciences Corporation stock shows the sell signal. See more of Exact Sciences Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.